Clinical Trials Logo

Primary Malignant Brain Tumors clinical trials

View clinical trials related to Primary Malignant Brain Tumors.

Filter by:
  • None
  • Page 1

NCT ID: NCT05622409 Recruiting - Clinical trials for Primary Malignant Brain Tumors

A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma

Start date: December 29, 2022
Phase:
Study type: Observational

Glioma is a major histological subtype of primary malignant brain tumors in Taiwan, with distinct epidemiological, clinical, and pathological features comparing to the other common cancer diseases. The disease rarely appears with metastatic disease at diagnosis, and with the most malignant subtype, glioblastoma, occurs with preference in mid- to old-age. For decades, primary malignant brain tumors has been known as one of the most desperate disease without successful improvement regarding of the treatment. Surgical resection is the principle for the primary treatment of gliomas. Chemotherapy and radiotherapy are often applied to patients for adjuvant therapy of surgery to pursue the treatment effect. Disappointedly, vast majority of the patients would eventually develop disease recurrence, leaving only limited choice for salvage treatment thereafter. The prognosis of these patients remains desperate, and thus a better understanding of this deadly disease is crucial for finding better therapeutic strategies for these patients.

NCT ID: NCT04171895 Active, not recruiting - Clinical trials for Advanced Care Planning

Communication Training for Caregivers In Advanced Care Planning

Start date: November 19, 2019
Phase:
Study type: Observational

The purpose of this research study is to develop and test a new communication training to help caregivers communicate more effectively with their loved ones and healthcare professionals about advanced care planning.

NCT ID: NCT02058745 Completed - Clinical trials for Primary Malignant Brain Tumors

SmartCare: Innovations in Caregiving Interventions

SmartCare
Start date: March 1, 2014
Phase: N/A
Study type: Interventional

This is a study to evaluate the effectiveness of using an established intervention for depressive symptom management in conjunction with a needs-based caregiver intervention for improving the psychological and physical health of family caregivers of persons recently diagnosed with a Primary Malignant Brain Tumor.

NCT ID: NCT01445691 Not yet recruiting - Glioblastoma Clinical Trials

More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery

Start date: November 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and utility of 5-aminolevulinic acid (ALA) for identifying your tumor during surgery. 5-ALA is not FDA approved at this time. When the investigators remove the tumor from your brain, it is important that they remove all of the tumor and not remove parts of normal brain. Sometimes this can be difficult because the tumor can look like normal brain. In some brain tumors, 5-ALA can make the tumors glow red under blue light. This may make it easier for your doctor to take out all of the tumor from your brain. The purpose of this study is to: - Make sure that 5-ALA helps the doctor remove more of the tumor. - Make sure 5-ALA does not cause any side effects. If you do not want to participate in this study, your doctor(s) will still do their best to remove all of the tumor in your brain. Whether or not you join this study will not change your treatment for your brain tumor.